Insomnia
Conditions
Keywords
Insomnia, Sleep, Telemedicine
Brief summary
Insomnia is a common medical condition that has a deleterious effect on emotional status, health-related quality of life, and has been associated with hospitalizations and all-cause mortality. Recently hospitalized patients who are recuperating in their homes would find it difficult to return for weekly visits with a clinical psychologist and therefore could benefit from the convenience of CBT-I treatment administered in the comfort of their homes via the wireless iPAD and video chat software. In patients who are recently discharged from the hospital, we wish to assess whether telemedicine-based CBT-I is comparable to conventional office-based CBT-I in the efficacy for treating insomnia. Research aiming to improve understanding of whether insomnia represents a modifiable risk factor for re-hospitalizations in patients who are high utilizers of healthcare services is an important area of future research.
Detailed description
Insomnia is a common and distressing medical condition that affects nearly 20% of U.S. adults, and persistent (or chronic) insomnia affects nearly 10-15% of U.S. adults. In a community-based prospective observational study, preliminary data suggests that insomnia is associated with hospitalizations due to cardiovascular, cancer, or any cause over a 4-year period. Cognitive Behavioral Therapy for Insomnia (CBT-I) is considered the gold-standard in the treatment of insomnia. There are 5 components of CBT-I, sleep restriction therapy, stimulus control instructions, relaxation training, cognitive therapy, and sleep hygiene education. In an ongoing study of CBT-I in recently hospitalized patients, the investigators found a high prevalence of insomnia (80%) and were able to administer CBT-I in the participants' home via iPADs with wireless connectivity and secure video-chat software. Recently hospitalized patients who are recuperating in their homes would find it difficult to return for weekly visits with a clinical psychologist and therefore could benefit from the convenience of CBT-I treatment administered in the patient's homes via the wireless iPAD and video chat software. The AASM SleepTM platform could conceivably allow performance of CBT-I without the added expense of an iPAD. The investigators are proposing to perform a non-inferiority trial of telemedicine CBT-I (AASM SleepTM) versus conventional office-based CBT-I that is performed in patients with insomnia who have been recently discharged from the hospital. The investigators will measure the following outcomes: insomnia severity index (primary outcome) and patient satisfaction. In the future, the investigators' program of research aims to improve understanding of whether insomnia represents a modifiable risk factor for re-hospitalizations in patients who are high utilizers of healthcare services. Specific Aim 1: To perform comparative effectiveness research of CBT-I administered by telemedicine versus conventional office-based CBT-I on insomnia severity in recently hospitalized patients. Hypothesis #1: In recently hospitalized patients with insomnia, after six weeks of CBT-I treatment, the mean improvement in ISI score among patients treated by telemedicine CBT-I (AASM SleepTM) would be no more than 3-points less than that in patients treated by conventional office-based CBT-I. Specific Aim 2: To perform comparative effectiveness research of CBT-I administered by telemedicine versus conventional office-based CBT-I on patient satisfaction. Hypothesis #2: In recently hospitalized patients with insomnia, after six weeks of CBT-I treatment, the mean improvement in patient satisfaction score (Consumer Assessment of Health Plans Survey \[CAHPS v4.0\] item) among patients treated by telemedicine CBT-I (AASM SleepTM) would be no more than 1-point less than that in patients treated by conventional office-based CBT-I.
Interventions
BEHAVIORALTelemedicine CBT-I
Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
BEHAVIORALConventional office-based CBT-I
Conventional office-based CBT-I
Sponsors
American Academy of Sleep Medicine
University of Arizona
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Masking description
Observers will be blinded to subjects group assignment
Intervention model description
Randomized Controlled Trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Medically ill patients with recent hospitalization who are being discharged to home. * ISI score of \> 10 (chronic insomnia) * Age \> 18 years * Ability to provide informed consent * Willingness to undergo sleep study
Exclusion criteria
* Presence of untreated sleep disorder that requires treatment independent of insomnia (Narcolepsy, restless leg syndrome, or REM sleep behavior disorder) * Patients with severe debilitating neurological disease (end-stage Alzheimer's, large stroke, or other debilitating neurological disease) or any other condition that renders patients incapable of providing informed consent * History of Bipolar disease; current or past (\< 6 months) history of suicidality or suicidal ideation * Active substance abuse or alcoholism * Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insomnia Severity Index (ISI) | Baseline and after receiving CBT-I (~6 weeks) | A 7-item questionnaire used to assess insomnia severity with a score ranging between 0 to 28. Each questionnaire item addresses an aspect about sleep that is rated by the respondent on a 5-point scale (i.e., 0=no problem & 4=very severe problem) Change in ISI score will be assessed between baseline and following CBT-I treatment over a 6 week period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Consumer Assessment of Health Plans Survey (CAHPS v4.0) item | Administered at baseline and at the end of receiving CBT-I (~6 weeks) | Health plan member's satisfaction with care on 0 to 10 scale (0 is the worst and 10 is the best health plan possible). Change in CAHPS score will be measured |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pittsburgh Sleep Quality Index (PSQI) | Administered at baseline and at the end of receiving CBT-I (~6 weeks) | Provides a subjective assessment of sleep quality. Change in PSQI score will be assessed between baseline and 6-week follow-up. |
| SF-36 Health Survey | Administered at baseline, at the end of receiving CBT-I (~6 weeks), at 2 weeks following treatment, and at 12 weeks following treatment | A 36 item health status assessment tool, which measures general health and quality of life. Change in various dimensions of the SF-36 will be assessed over the 6-week period. |
| Wake After Sleep Onset (WASO) | Sleep diaries are completed daily and actiwatch is worn continuously during the treatment period (~6 weeks) | WASO is defined as the number of minutes spent awake after sleep onset. This is going to be measured by wrist actigraphy and sleep diaries. Change in WASO will be assessed over the intervention period |
| Healthcare utilization | Administered at the time of hospital discharge and at the end of receiving CBT-I (~6 weeks) | Composite number of visits to any of the following locations of healthcare service for care delivery: Emergency room, urgent care, as well as unscheduled and scheduled clinic visits. |
| Epworth Sleepiness Scale (ESS) | Administered at baseline and at the end of receiving CBT-I (~6 weeks) | A measure of sleepiness. Change in ESS score will be assessed |
| Re-hospitalizations | Administered at the time of hospital discharge and at the end of receiving CBT-I (~6 weeks) | Composite number of hospital readmissions over 6 weeks. |
| Sleep Onset Latency (SOL) | Sleep diaries are completed daily and actiwatch is worn continuously during the treatment period (~6 weeks) | SOL is the number of minutes that it takes to fall asleep. This is going to be measured by wrist actigraphy and sleep diaries. Change in SOL will be assessed over the intervention period |
Countries
United States
Contacts
Primary ContactSairam Parthasarathy, MD
Outcome results
None listed